Caribbean International Holdings Wholly Owned Subsidiary Announces It Has Begun Processing Applicants for Treatments Via Its ...
May 05 2014 - 5:00PM
Strategy is to Screen and
Qualify Viable Applicants/Patients for Treatment in DR Through
Regenerative BioScience, Inc.
Treatments Have Already
Commenced
Caribbean International Holdings (Pink
Sheets:CIHN) through its subsidiary, Regenerative BioScience, Inc.,
("RBS") previously announced on May 2, 2014, that it had appointed
Dr. Leonel Liriano as its Medical Director, today announced, in a
further development, that via the Company's new website
(http://www.regenerativebioscience.com/index.html) is now fully
operational and it has begun processing initial requests for its
no-cost cost complimentary consultations regarding the applicant's
suitability to qualify for Company's revolutionary stem cell
procedures.
Adult stem cells work as the repairmen of the body by
replenishing and regenerating damaged tissues and cells. Certain
conditions have shown marked improvement when treated with adult
stem cells taken from the patient's own body. Regenerative
BioScience is a revolution in healthcare using a patient's own
adult stem cells. There is little to no risk of rejection when a
patient's own stem cells are used.
As anticipated, RBS is averaging 3 to 5 applicants per week
during its initial rollout period. Eight patients have now been
fully qualified, and three are ready to go to the DR in the next
two weeks, for their procedures to commence under the guidance of
Dr. Liriano.
Each application or health record is initially processed and
then sent to Dr. Liriano for his personal diagnosis. After Dr.
Loriano's diagnosis, then representatives of both CIHN and RBS make
the arrangements, as per Dr. Liriano instructions, for commencement
of treatment.
Dr. Liriano, as previously reported, had treated well known
athlete, Bartolo Colon, who was out of baseball for nearly 2 years
because of a serious shoulder injury, but returned to the sport and
became an All-Star thanks to a stem cell procedure where stem cells
were taken from his body and then re-injected into his shoulder by
Dr. Liriano. This injury previously may have required surgery to be
repaired or the player would be forced into early retirement.
Steven Swank, Chairman and CEO of Caribbean International
Holdings, stated, "We are happy with the number of applications we
have received during this ramp-up period and the patients we have
treated have shown great improvement, and are very satisfied with
their progress."
Swank went on to say: "We at CIHN and RBS know that stem cells
can work wonders and are pleased that our web site admissions
program is operational, and our patient coordinators are doing
their job. I am personally very gratified to announce eight
patients have now been fully qualified, and three are ready to go
to the DR in the next two weeks, for their procedures to commence
under the guidance of Dr. Liriano. Since our contract was signed
with Dr. Liriano on February 1st in New York, our day-to-day
business has become more exciting for all of us here at CIHN, and
the promise of great business to come seems inevitable to myself
and our employees."
On another matter, the Company announced the opening of new
treatment locations in Guadalajara, Mexico, and Cabo St Lucas, and
is also negotiating to install a proprietary lab in Santa Domingo,
Dominican, Republic.
Additionally the Company announced that on May 15th to the 17th,
Rafael Gonzalez who is on the Company's advisory board, will be a
guest speaker at the 22nd Annual World Congress on ANTI-AGING,
REGENERATIVE & AESTHETIC MEDICINE, in Orlando, Florida
About The Company:
Caribbean International Holdings, Inc. is a holding company for
Regenerative BioScience, Inc. ("RBSI"). The Company subsidiary RBSI
is focused on helping individuals protect and ensure their future
quality of life through Adult Stem Cell Incubation and the practice
of regenerative medicine in the United States and the Dominican
Republic. RBSI's mission is not only to allow patients to store
their Stem Cells for future use, but also perform patient funded
stem cell therapies for degenerative diseases such as MS,
Arthritis, Degenerative Heart Diseases, Diabetes and a host of
experimental therapies in the brain trauma disease sector including
CTE. The goal is to become a global leader in establishing
protocols that can be patented and utilized to heal patients around
the world.
For more information go to:
http://www.regenerativebioscience.com/index.html
Forward-Looking Statements
Except for statements of historical fact, the matters discussed
in this press release are forward looking and made pursuant to the
Safe Harbor provisions of the Private Securities Litigation Reform
Act of 1995. "Forward-looking statements" describe future
expectations, plans, results, or strategies and are generally
preceded by words such as "future," "plan" or "planned," "expects,"
or "projected." These forward-looking statements reflect numerous
assumptions and involve a variety of risks and uncertainties, many
of which are beyond the company's control that may cause actual
results to differ materially from stated expectations. These risk
factors include, among others, limited operating history,
difficulty in developing, exploiting and protecting proprietary
technologies, intense competition and additional risks factors as
discussed in reports filed by the company with the Securities and
Exchange Commission, which are available on at
http://www.sec.gov.
CONTACT: Investor Contact:
BioScience
(941) 924-9400
BioStem Technologies (PK) (USOTC:BSEM)
Historical Stock Chart
From Sep 2024 to Oct 2024
BioStem Technologies (PK) (USOTC:BSEM)
Historical Stock Chart
From Oct 2023 to Oct 2024